Isolated Subcarinal Lymph Node Recurrence 24 Years After Treatment for Primary Tracheal Adenoid Cystic Carcinoma Authors: Yuhei Suzuki, Hiroaki Ikushima, Mitsuhiro Yamamoto, Yutaro Ueki, Aya Shinozaki‐Ushiku, Masanori Kawakami, Akihisa Mitani, Yosuke Masamoto, Hidenori Kage Published: 2026 ABSTRACT ABSTRACTAdenoid cystic carcinoma (ACC) is a slow‐growing malignancy characterised by late recurrence, making long‐term follow‐up essential. We report a case of 55‐year‐old woman who presented with exudative right pleural effusion and subcarinal lymphadenopathy after haematopoietic stem cell transplantation for myelofibrosis. She had undergone surgery and radiotherapy for primary tracheal ACC 24 years prior. Although haematologic disease‐related conditions were initially suspected, endobronchial ultrasound‐guided transbronchial needle aspiration of the subcarinal lymph node revealed isolated recurrence of ACC, with no evidence of pleural malignancy on pleural biopsy results. Because ACC progresses more slowly than many other malignancies, the growth rate alone does not reliably distinguish benign from malignant lesions. Therefore, a history of ACC should always be considered, and a tissue diagnosis should be pursued when clinically indicated. Introduction Adenoid cystic carcinoma (ACC) is a malignant tumour that most commonly arises in the salivary glands and can also occur in the trachea. Primary tracheal malignancies are rare, with an annual incidence of approximately 0.1–0.2 cases per 100,000 population. Among them, ACC is the second most common histological subtype after squamous cell carcinoma, accounting for approximately 16% of cases [1]. ACC shows slow progression, and late recurrence has been reported, sometimes after approximately 30 years of disease‐free survival. Although lymph node metastasis at initial treatment has occasionally been described, the lung is considered the most common site of recurrence, and reports of lymph node recurrence are limited. We report a case of isolated subcarinal lymph node recurrence 24 years after treatment for primary tracheal ACC (TACC), which required differentiation from haematologic disease‐related conditions after haematopoietic stem cell transplantation (HSCT) for myelofibrosis. Case Report A 55‐year‐old woman was referred to our department for evaluation of an increasing and loculated right‐sided pleural effusion and subcarinal lymphadenopathy. At 31 years of age, she underwent surgery and radiotherapy (60 Gy in 30 fractions) for ACC and was regularly followed up for recurrence. Because blast‐like cells appeared during the follow‐up of JAK2V617F+ polycythaemia vera, she was referred to our haematology department at 52 years of age and was subsequently diagnosed with secondary myelofibrosis. Haploidentical peripheral blood stem cell transplantation was performed at 54 years of age, after which immunosuppressive therapy with ruxolitinib, prednisolone and cyclosporine was administered for chronic graft‐versus‐host disease. Right‐sided pleural effusion was noted during the transplantation course, but it decreased as the concomitant cardiac tamponade improved. At 55 years of age, a gradual increase and loculation of the right pleural effusion and the subcarinal lymphadenopathy were noted. Chest computed tomography (CT) showed that the subcarinal lymph node measured approximately 13 mm and had changed little in size over 5 months (Figure 1B,C). Although an accurate assessment is difficult on non‐contrast CT, subcarinal lymphadenopathy appears to have developed around the time of HSCT and gradually enlarged over the subsequent 14 months (Figure 1A,C). Positron emission tomography (PET) showed uptake in the subcarinal lymph node with a maximum standardised uptake value of 18.7, whereas there was little uptake in the right pleura. A pleural fluid analysis revealed dark‐red exudative effusion with lymphocyte predominance (89% lymphocytes), a glucose level of 69 mg/dL, pH 7.185 and LDH of 258 U/L; however, the culture results were negative and cytology showed no malignancy. Bronchoscopy revealed no obvious recurrence at the stump. Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) of the subcarinal lymph node revealed recurrent ACC (Figure 2). Thoracoscopic right pleural biopsy under local anaesthesia revealed no malignancy on histopathologic examination. (A) Non‐contrast CT obtained 1 month after transplantation and 14 months before presentation to our department suggested subcarinal lymphadenopathy. (B) Contrast‐enhanced CT obtained 5 months before presentation to our department, showing subcarinal lymphadenopathy and right‐sided pleural effusion. (C) PET obtained at the initial visit. The size of the lymph node was essentially unchanged. No definite pleural uptake was observed, whereas the subcarinal lymph node showed intense uptake, with a maximum standardised uptake value of 18.7. Haematoxylin and eosin‐stained specimen showing histological features consistent with adenoid cystic carcinoma. The tumour shows tubular and cribriform structures composed of dual populations of ductal epithelial and myoepithelial cells, accompanied by basement membrane‐like and myxoid stroma. Therefore, the patient was diagnosed with isolated subcarinal lymph node recurrence of ACC. The pleural effusion was considered more likely to be related to her haematologic disease. She was referred to the Department of Thoracic Surgery for surgical treatment. Resection of the lymph node lesion has been planned. The patient is currently on follow‐up for careful monitoring. Discussion ACC is characterised by slow progression and very late recurrence, and long‐term follow‐up has repeatedly been emphasised. Reviews of primary TACC have also described these features, and recurrence as late as 29 years after surgery, including local recurrence, has been reported [2]. Although the lung is considered the most common site of recurrence in TACC, lymph node recurrence appears to be less frequently reported [3]. In that context, the present case is clinically important because it demonstrates that isolated mediastinal lymph node recurrence can occur after a long disease‐free interval. The short‐axis diameter of the subcarinal lymph node was approximately 13 mm, with little change in its size over approximately 5 months. However, such short‐term radiologic stability does not exclude recurrence in ACC. In addition, the patient had a complex haematologic background after HSCT, which broadened the differential diagnosis to include haematologic disease‐related conditions. The need to differentiate these conditions prompted us to order a PET scan. Given the FDG avidity of the subcarinal lymph node on the PET scan and remote history of ACC, we decided to perform EBUS‐TBNA. In this setting, tissue confirmation was essential. EBUS‐TBNA enabled a definitive diagnosis of recurrent ACC in the subcarinal lymph node and played a central role in distinguishing recurrence from other possible causes of mediastinal lymphadenopathy. This case therefore underscores the importance of PET and pursuing pathological evaluation when clinically indicated, even when radiologic progression appears limited. With regard to the pleural effusion in this case, malignant pleural effusion due to ACC cannot be excluded, but a definite diagnosis is not possible at present, and we currently consider the effusion to be more likely related to the patient's haematologic disease. Malignant pleural effusion due to ACC is relatively rare, particularly in cases originating from the trachea. In a previously reported case of primary TACC with malignant pleural effusion, pleural fluid cytology was nondiagnostic and the diagnosis was ultimately made by thoracoscopic biopsy of diffuse pleural nodules [4]. In the present case, repeated pleural fluid examinations, thoracoscopy, and PET all failed to yield findings suggestive of malignant pleural effusion, and the pleural biopsy showed no definite malignancy. Therefore, pleural effusion related to haematologic conditions such as graft‐versus‐host disease was considered as a possible cause. However, because ACC progresses slowly, careful follow‐up is necessary. Lymphadenopathy due to ACC may be overlooked as a recurrent disease because of its slow progression, and both physicians and patients need to remain aware of this possibility. When mediastinal lymphadenopathy is incidentally identified on CT, management is generally based on short‐axis diameter, lung parenchymal findings and past medical history. Additional evaluation is recommended when lymphadenopathy progresses [5]. For patients with a history of ACC, isolated mediastinal lymphadenopathy should prompt consideration of late recurrence, even after a long disease‐free interval. Therefore, clinicians should emphasise the importance of long‐term follow‐up and informing physicians of this history. This case highlights that radiologic stability should not preclude tissue diagnosis in patients with a history of ACC, particularly in complex clinical contexts such as post‐HSCT. Author Contributions Y.S. and H.I. drafted the manuscript. All authors were directly involved in the treatment, critically revised the manuscript and approved the final version. Funding The authors have nothing to report. Consent The authors declare that written informed consent was obtained for the publication of this manuscript and accompanying images using the consent form provided by the journal. Conflicts of Interest The authors declare no conflicts of interest.